STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Stoke Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$24.82+0.65 (+2.69%)
Close on Oct 19, 2026
- Market cap
- $1.64B
- P/E (TTM)
- –
- Dividend yield
- –
Stoke Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Market Cap | $1.60B | $164.85M |
| Enterprise Value | $1.31B | $87.06M |
| PS Ratio | 58.05 | 3.60 |
| PB Ratio | 4.63 | 2.03 |
| P/TBV Ratio | 4.63 | 2.31 |
Enterprise value
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 47.44 | 2.43 |
Income (trailing twelve months)
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Revenue | $27.59M | $57.94M |
| Operating Income | -$223.38M | -$21.44M |
| Net Income | -$207.90M | -$22.46M |
| EBITDA | -$223.38M | -$16.91M |
| EPS (Diluted) | -$3.41 | -$0.83 |
Margins
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Operating Margin | -809.7% | -44.5% |
| Profit Margin | -753.6% | -39.2% |
| EBITDA Margin | -809.7% | -31.3% |
| FCF Margin | -654.9% | -8.85% |
Returns
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -61.1% | -53.1% |
| Return on Assets (ROA) | -53.4% | -41.0% |
| Return on Invested Capital (ROIC) | -252.2% | -32.0% |
| Return on Capital Employed (ROCE) | -63.5% | -37.8% |
Growth
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | -86.2% | 6.01% |
| Net Income Growth (YoY) | -496.1% | -37.7% |
| EPS Growth (YoY) | -501.2% | -29.2% |
| FCF Growth (YoY) | -395.5% | 2.34% |
| Revenue Growth (3Y CAGR) | 145.9% | 2.25% |
Balance sheet
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $292.82M | $62.42M |
| Net Cash (Debt) | $292.82M | $15.68M |
| Net Cash Per Share | $4.54 | $0.66 |
| Equity (Book Value) | $345.55M | $48.79M |
| Book Value Per Share | $5.36 | $1.36 |
| Tangible Book Value | $345.55M | $23.06M |
| Working Capital | $280.61M | $75.77M |
Financial position
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.69 | 3.30 |
| Quick Ratio | 7.15 | 2.39 |
| Interest Coverage | -4856.02 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$177.99M | -$12.35M |
| Capital Expenditures | -$2.69M | -$1.06M |
| Free Cash Flow | -$180.68M | -$20.28M |
| FCF Per Share | -$2.80 | -$0.42 |
Efficiency
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.07 | 0.38 |
| Revenue Per Employee | $162.28K | $398.96K |
| Profits Per Employee | -$1.22M | -$703.34K |
| Employee Count | 170 | 74 |
Dividends and yields
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -13.0% | -22.7% |
| FCF Yield | -11.3% | -9.07% |
Shares
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 64,526,200 | 58,179,650 |
| Shares Change (YoY) | 5.29% | 11.1% |
| Shares Change (QoQ) | 0.26% | 0.54% |
| Float | 37,672,000 | 49,173,100 |
| Shares Held by Insiders | 41.6% | 11.6% |
| Shares Held by Institutions | 119.9% | 59.4% |
Taxes
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$1.28M | $91.50K |
Scores
| Measure | Stoke Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 16.73 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Stoke Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.